Endocrine Abstracts

Background: Cardiovascular safety is important for antidiabetic agents. This study followed the ICH E14 guideline to examine the effect of the oral dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin on the cardiac QT interval in healthy volunteers.Methods: This thorough QT study of linagliptin was performed in healthy subjects, using 5 mg (therapeutic dose) and 100 mg. The randomised, single-dose, placebo-controlled, double-blind, four-way crossover st...